SUPN
Supernus Pharmaceuticals Inc
NASDAQ: SUPN · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$48.55
-0.29% today
Updated 2026-04-29
Market cap
$2.80B
P/E ratio
—
P/S ratio
3.89x
EPS (TTM)
$-0.68
Dividend yield
—
52W range
$29 – $60
Volume
0.7M
Supernus Pharmaceuticals Inc (SUPN) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-5.36%
Operating margin
5.57%
ROE
-3.68%
ROA
1.14%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2007 | $4.23M | $-17.27M | 100.00% | -449.92% | -408.04% |
| 2008 | $8.89M | $-33.48M | 100.00% | -290.93% | -376.67% |
| 2009 | $37.92M | $460000.00 | 122.65% | 10.59% | 1.21% |
| 2010 | $106000.00 | $-38.46M | 12,745.28% | -37,851.89% | -36,285.85% |
| 2011 | $803000.00 | $56.00M | 100.00% | -4,701.37% | 6,974.22% |
| 2012 | $1.48M | $-46.28M | 100.00% | -2,849.26% | -3,127.30% |
| 2013 | $12.02M | $-92.27M | 90.81% | -515.18% | -767.73% |
| 2014 | $122.05M | $19.87M | 95.28% | 19.85% | 16.28% |
| 2015 | $144.43M | $14.02M | 94.17% | 12.23% | 9.70% |
| 2016 | $215.00M | $91.22M | 94.43% | 25.22% | 42.43% |
| 2017 | $302.24M | $57.28M | 94.97% | 32.93% | 18.95% |
| 2018 | $408.90M | $110.99M | 96.24% | 35.33% | 27.14% |
| 2019 | $392.75M | $113.06M | 95.76% | 37.83% | 28.79% |
| 2020 | $520.40M | $126.95M | 89.92% | 33.38% | 24.39% |
| 2021 | $579.77M | $53.42M | 87.05% | 14.84% | 9.21% |
| 2022 | $667.24M | $60.71M | 86.93% | 6.91% | 9.10% |
| 2023 | $607.52M | $1.32M | 86.21% | -0.87% | 0.22% |
| 2024 | $661.82M | $73.86M | 88.23% | 12.34% | 11.16% |
| 2025 | $718.95M | $-38.55M | 89.63% | -5.13% | -5.36% |